Video Hero Poster

Enhancing critical medicines

Learn More

ADVANZ PHARMA is a global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals. We are committed to improving patients' lives by providing and enhancing the specialty and hospital medicines they depend on.

Since the acquisition of the majority of Intercept Pharmaceuticals’ subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S., ADVANZ PHARMA has a sizable presence in the treatment of rare diseases with Ocaliva® as an orphan drug in PBC (a progressive autoimmune disease affecting the liver).

Our portfolio of specialty, hospital, and rare disease medicines focuses on Hepatology, Gastroenterology, Anti-infectives, Endocrinology and Critical Care medicines with the ambition to make a meaningful difference for patients.

We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values Entrepreneurship, Speed, and Integrity.

Our portfolio —

At ADVANZ PHARMA, we serve patients with specialty, hospital, and rare disease medicines with a focus on Hepatology, Gastroenterology, Anti-infectives, Endocrinology and Critical Care.

We have a broad portfolio of overall more than 180 brands, and we bring our medicines to patients in over 80 countries.

Careers & Culture —

The success of any company is driven by its people, and we are no different. We aim to be the best team in the industry by embracing challenges and change. We live our company values Entrepreneurship, Speed, and Integrity.

Responsibility —

ADVANZ PHARMA is committed to bringing important medicines to even more patients across the globe and to improving the lives of patients by providing and enhancing the specialty and hospital medicines they depend on.

Our Partnerships —

Partnerships are a fundamental part of our business.. We work with >300 partners in production, development, portfolio licensing, and commercialization. We cooperate very closely with them and invest significantly to help broaden patient access and to improve health outcomes.

Investors —

Our vision is clear – to be the best specialty and hospital pharma partner in Europe & Canada. In addition, we can leverage our operations centre of excellence and our global network of partnerships to bring our medicines to patients.

We will do this by continuing to expand our business via acquisitions, in-licensing agreements, and launches to drive growth, especially in our focus therapeutic areas as well as more broadly in rare diseases.

Latest News —

Image for ADVANZ PHARMA to receive exclusive rights from PolyPid to commercialize D-PLEX100 in Europe

Press Releases — 03 Aug 2022

ADVANZ PHARMA to receive exclusive rights from PolyPid to commercialize D-PLEX100 in Europe

Learn more
Image for ADVANZ PHARMA completes acquisition of Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Press Releases — 01 Jul 2022

ADVANZ PHARMA completes acquisition of Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Learn more
Image for ADVANZ PHARMA to acquire Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Press Releases — 05 May 2022

ADVANZ PHARMA to acquire Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

Learn more
Image for Steffen Wagner assumes his position as new Chief Executive Officer at ADVANZ PHARMA

Press Releases — 31 Mar 2022

Steffen Wagner assumes his position as new Chief Executive Officer at ADVANZ PHARMA

Learn more
Image for Cidron Aida Finco S.à r.l.  Successful pricing of €175.0 million 5% Senior Secured Notes due 2028

Press Releases — 20 Jan 2022

Cidron Aida Finco S.à r.l. Successful pricing of €175.0 million 5% Senior Secured Notes due 2028

Learn more
Image for Cidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028

Press Releases — 17 Jan 2022

Cidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028

Learn more